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2006

was a year of both celebration and
circumspection for those of us dedicated

to HIV prevention. We welcomed the renewed commitment
to prevention expressed by leaders from civil society, the
private sector and government at the XVI International
AIDS Conference in Toronto. Calls from Toronto for new
HIV-prevention tools echoed earlier discussions at the
biennial international Microbicides Conference in Cape

Els Borst-Eilers, M.D., Ph.D.
Chair of the Board

Zeda F. Rosenberg, Sc.D.
Chief Executive Officer

Town, South Africa – the first microbicides conference
held in sub-Saharan Africa, where women are affected by
HIV/AIDS more profoundly than anywhere else in the world.
Throughout last year, HIV-prevention research made significant strides. Studies in Kenya and Uganda showed that male
circumcision can significantly reduce a man’s risk of becoming infected with HIV. Prevention research continued on many
additional fronts, including advanced clinical trials of microbicides, oral pre-exposure prophylaxis, HIV vaccines, herpes
virus suppression and diaphragms.
However, we were also reminded of the challenges in conducting HIV-prevention research. Some microbicide studies
closed because the numbers of new HIV infections were too low to show meaningful differences between the placebo and
microbicide groups. In addition, in early 2007, trials of the candidate microbicide cellulose sulfate were stopped because of
concerns that the product may increase women’s risk of acquiring HIV.
The sponsors of the cellulose sulfate trials, CONRAD and Family Health International, acted swiftly to stop the trials and
provide preliminary results, reflecting the commitment of the microbicide field to protect women participating in clinical
studies. The closure of these trials illustrates how difficult it can be to develop new drugs and prevention technologies for
HIV. But it also demonstrates a broad commitment to ensuring that new prevention tools are safe and effective. We saw this
clearly in the days and weeks following the announcement, as a number of HIV advocacy groups in South Africa publicly
reaffirmed their support for microbicide development.

promising next-generation microbicide candidates – based on proven antiretroviral strategies – through pre-clinical and
clinical development. From our new office in South Africa, IPM is overseeing a series of clinical and epidemiological studies.
These latter studies are designed to estimate HIV incidence at potential trial sites, helping to ensure that future efficacy
trials can accurately measure the effectiveness of microbicide candidates.
In 2006, IPM continued to build new relationships among funders and industry. Gilead Sciences, Inc., granted IPM and CONRAD
royalty-free licences to develop tenofovir as a microbicide. Four pharmaceutical companies have now provided IPM with
such rights, demonstrating a significant positive trend within the industry. The governments of Belgium, France and
Germany contributed to IPM for the first time, building on new 2006 commitments from existing funders including Canada,
the European Commission, Ireland, the Netherlands, Norway, Sweden and the United States.
The past year has seen many challenges, but the need for a microbicide remains as urgent as ever. Almost 18 million women
around the world are infected with HIV, and thousands more become infected every day. Prevention is the only way out of this
epidemic, and a safe and effective microbicide will be a vital tool. IPM remains committed to making microbicides a reality. t
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The International Partnership for Microbicides (IPM) remains focused on expanding the microbicide pipeline and moving



Pressing needs,
Potential solutions: 			
			 			
microbicides
Status of the HIV/AIDS epidemic
The devastation is all too familiar: In the last 25 years,
HIV/AIDS has claimed the lives of 25 million people

Women ARE at special risk

worldwide. Approximately 14,000 men, women and

In the continuing tragedy of the epidemic, more women

children are newly infected with HIV daily. Each case has

than ever before are living with HIV. In the past two years,

a profound impact on entire communities and multiple

the number of women living with HIV has increased by

generations. Children are orphaned — more than 15 million

one million to 17.7 million. The epidemic is having a

children to date, including 12 million in sub-Saharan

devastating impact on national health indicators, espe-

Africa. Parents die and grandparents must care for young

cially for women, where in Zimbabwe, for example, life

grandchildren. And communities have lost a generation

expectancy is only 34 years. Marriage, once thought to be

of people who can contribute to their society and economy.

a refuge from the epidemic, is now a significant risk factor
in many places. According to the UNFPA, more than 80
percent of new HIV infections in women occur in marriage
or a long-term relationship with a primary partner.

In 2006, IPM:



l Expanded the microbicide pipeline and advanced
products in pre-clinical development

l Integrated the concerns and perspectives of
community members into microbicide development

l Investigated new microbicide formulations,
developed trial sites and completed key safety trials

l Increased support for microbicides and prepared
for access to products

Microbicides can play a role
The International Partnership for Microbicides (IPM) is
accelerating the development and availability of safe,

IPM is expediting development

effective microbicides — vaginal products that could

IPM, a non-profit product development partnership,

prevent HIV infection during sexual intercourse.

operates at the crossroads of many different organisations

As a female-initiated measure, microbicides could give

and communities interested in developing effective

women a powerful tool for protecting themselves from

microbicides. Through IPM, scientists, social and

infection, and thus be an invaluable component of any

economic development organisations, private sector

comprehensive response to the epidemic.

companies, community leaders and women themselves

HIV prevention. IPM serves as a resource for this diverse

As a female-initiated measure,
microbicides could give women
a powerful tool for protecting
themselves from HIV infection.

community by performing and funding research and
development, helping build clinical site capacity,
supporting and conducting clinical trials, sharing
knowledge, increasing public support, facilitating critical
alliances and ensuring that women in developing
countries will have broad access to microbicides
once they become available.
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are better able to work towards their common goal of



Advancing microbicide
							Development
Expanding the pipeline:
next-generation compounds
IPM plays an essential role in HIV-prevention research by

Seeking innovative
intellectual property
agreements

identifying and developing new microbicide compounds.

IPM leverages expertise and resources from the private

Promising compounds are developed either by funding

sector to advance microbicide research by developing

other organisations’ efforts or through direct work at

royalty-free licensing agreements with pharmaceutical

IPM. By exploring multiple candidates with diverse

and biotechnology companies. These agreements allow

mechanisms of action, IPM and its research and devel-

IPM to study and develop promising compounds, alone as

opment (R&D) partners are able to increase the chances

well as in combinations, and, if they prove effective,

of success and expand the number of effective options

to distribute them in resource-poor settings at low cost.

that will ultimately be available to women.



First-generation microbicide candidates, which are now in

Exploring controlled-release
formulations

efficacy trials, are non-specific inhibitors that seek to block

IPM is focusing on formulating microbicides in ways

HIV from interacting with its target cells in the vagina.

that allow for controlled release of the drug over time,

IPM and others are now researching next-generation

so that products can be discreetly applied hours, days

products that specifically target HIV and the cells it infects.

or even weeks in advance of intercourse, thus providing

Based on antiretroviral drugs (ARVs) that are already being

protection when unanticipated sex occurs. The vaginal

used successfully to treat AIDS, these next-generation

ring, a flexible device made of a polymer, can be inserted

microbicides are being formulated for sustained release

and removed manually. New types of rings are being

either alone or in combination with other microbicides.

researched, as well as other formulations including

The ultimate goal of IPM’s product development efforts

once-a-day gels, films and vaginal tablets. ARV compounds,

is to create effective anti-HIV microbicides that can be

including IPM’s candidates, lend themselves to a wide

used once a day or even less frequently.

variety of formulations.

Path to diversification
IPM is furthering the development of multiple compounds
with different mechanisms of action, both by conducting its
own work and by providing funding to other R&D organisations.

IPM
Compounds

IPM-Supported
Compounds

BMS793
M167
M872
M882

Dual Mechanism (Locus)
Small Molecule (Locus)
IQP 1187 (Samjin)
IQP 0528 (Samjin)
IQP 0558 (Samjin)

Dapivirine
Tenofovir

Dual Mechanism (Locus)
IQP 1187 (Samjin)
IQP 0528 (Samjin)
IQP 0558 (Samjin)

Free virus

Attachment
Fusion

Replication
(reverse
transcriptase)

Budding
Maturation

By exploring multiple candidates with diverse mechanisms of
action, IPM and its partners are able to increase the chances
of success and the number of effective options that will ultimately be available to women.
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Microbicide development
Progress this year:
l

Prioritised Development of Dapivirine,

with an international group of process development

IPM’s lead Candidate

organisations, and is proceeding with analytical and

IPM evaluated multiple new gel formulations of its lead

pre-clinical work. IPM also made advancements in

candidate microbicide – dapivirine – a non-nucleoside

optimising the complex and lengthy synthesis process,

reverse transcriptase inhibitor licensed from Tibotec

resulting in substantial yield improvements. This will

Pharmaceuticals, Ltd. (a subsidiary of Johnson & Johnson).

reduce the number of steps it will take to manufacture

These new formulations include gels with completely

the compound, making it easier and potentially less

solubilised drug, gels with drug in suspension and

costly to produce.

saturated solution gels. In addition, IPM is working with
Warner Chilcott to explore sustained release delivery in
various vaginal ring formulations.
l

Obtained rights to tenofovir as a microbicide

Together with CONRAD of the Eastern Virginia Medical
School, IPM has entered into an agreement with Gilead

PROGRESSed with New Merck and BMS

Sciences, Inc., to explore the development of the HIV/AIDS

Compounds

treatment drug tenofovir as an anti-HIV microbicide. Like

Merck & Co., Inc., granted IPM a licence in 2005 to develop

IPM’s agreements with other pharmaceutical companies,

its compound M167 as a microbicide. M167 is an ARV

this arrangement allows distribution of microbicides on

that blocks a specific cellular receptor (CCR5) so the

a royalty-free basis in resource-poor countries.

virus cannot attach to target cells. In 2006, IPM worked
with ScinoPharm in Taiwan and China to optimise the
synthesis and manufacturing of M167, and has begun
formulation and combination virology studies.

IPM has also been granted a licence from Bristol-Myers
Squibb to develop its ARV compound BMS793, which
blocks HIV infection by attaching to a protein on the viral
surface. IPM has arranged for the manufacture of BMS793



l

l

Began studies of new combination microbicides

IPM started basic virological assessment of combinations
of multiple microbicides. These studies are designed to
examine in vitro effectiveness and compatibility of dapivirine with other drugs, including M167 and tenofovir.

Scientific Advisory Board
The Scientific Advisory Board (SAB) was created
in 2002 to provide ongoing, high-level scientific
advice to IPM. IPM’s scientific agenda is based
on a set of decision-making criteria approved by
the SAB in 2003. Due to its size, the full SAB does
not meet regularly. IPM staff consults as needed
l

Proceeded with new vaginal ring designs

In its efforts to identify the safest, most effective and

with individual SAB members who have expertise
in particular areas of microbicide research and/
or drug development. IPM provides SAB members

affordable delivery system options for women, IPM

with updates on its work, including a compre-

worked with Queen’s University Belfast to develop a

hensive annual report on its science program.

potentially less expensive matrix ring, and also began
studying biodegradable ring technology.

IPM established an SAB Executive Committee
to meet annually, beginning in 2006. The Execu-

l

Continued exploring innovative formulations

tive Committee is comprised of members from

In collaboration with New Zealand’s Auckland University,

the broader SAB with particular expertise in

IPM developed a prototype slow-release microbicide

drug development, ARV science, microbicide

vaginal tablet. No applicator is required and the tablet
can be inserted independently of intercourse. IPM and
other development partners also began early work on
film formulations, in which the microbicide is affixed to
a film and gradually released as the film dissolves.

development, clinical evaluation, delivery system
expertise and other relevant areas. The Executive
Committee reviews IPM’s scientific agenda and
work over the previous year, and advises IPM
staff on their research plans and priorities for the
coming year.
International Partnership for Microbicides l ANNUAL REPORT 2006



Advancing the testing
of products for women
MOving Microbicides to
Clinical trials

Testing for safety

All microbicide candidates must go through a rigorous

under very carefully controlled clinical conditions, such

programme of laboratory screening and testing to ensure that

as recent IPM safety studies of dapivirine gel conducted

they have an adequate safety profile prior to being tested

in Belgium and Africa. Larger safety studies, in which

in humans. This intensive program of pre-clinical tests

the microbicide is administered to a wider range of women

can take many months to complete. Once laboratory tests

over longer periods, can then be conducted in order to

have been performed satisfactorily, candidate microbicides

gain a better understanding of the safety of the product.

can be advanced through a series of human clinical trials

Clinical safety trials can take one to two years to complete.

designed to test their safety and efficacy (the ability to
prevent HIV infection). To test efficacy, trials must be
conducted in locations with high HIV incidence. IPM is
identifying and developing up to 20 clinical trial sites.



Initial safety trials involve small numbers of women

Efficacy trials: Testing the
ability to prevent HIV

Identifying test sites for
efficacy trials

Only when the safety studies have been completed and

Reliable trial data is in everyone’s interest – study

efficacy trial sites established can clinical efficacy trials be

participants, researchers and women worldwide.

performed to test the ability of the microbicide to prevent

In cooperation with national and regional authorities,

HIV infection. These prevention trials involve thousands

researchers take a critical step in ensuring quality data

of women volunteers and need to be conducted in high-

when they select trial sites. Efficacy trial sites are

incidence locations so that researchers can compare

established in areas where there are high rates of new

new infection rates among those who use the candidate

HIV infections to ensure that researchers are able to

microbicides with those who use placebos. Efficacy trials

measure the potential impact of a candidate microbicide

can last three years or longer. IPM is preparing for

in reducing the rate of new infections. Background HIV

efficacy trials of dapivirine and other future microbicides.

incidence rates traditionally have been measured through
cohort studies which involve hundreds or even thousands

Establishing guidelines for
conducting trials to the
highest ethical standards

of people who share certain characteristics or behaviours

IPM is committed to implementing microbicide clinical

followed over time to detect new HIV infections. Newer

trials that meet the highest ethical and regulatory standards,

laboratory seroincidence studies have the potential to

sustain broad community support and leave participating

measure HIV incidence far more quickly across a cross-

communities better off. IPM will work closely with local

section of the community. IPM routinely conducts site

and national governments and development partners so

assessment and evaluation visits, most recently at 12

that support for participants and communities involved

potential sites in South Africa and 10 in Kenya, Mozambique,

in clinical trials can be a shared responsibility.

Namibia, Nigeria, Rwanda, Tanzania and Zimbabwe.

– such as HIV-negative women who might volunteer to
International Partnership for Microbicides l ANNUAL REPORT 2006

participate in future efficacy trials. These individuals are



Testing products for women
Progress this year:
l

Completed gel safety studies

IPM and its partners completed safety trials of dapivirine

l

Finalised plans for a safety and acceptability
study of placebo vaginal rings

in a gel formulation in Rwanda, South Africa and Tanzania.

IPM finalised a protocol for a placebo vaginal ring

More than 100 women volunteers participated in these

safety and acceptability study to be conducted in Kenya,

safety trials.

South Africa and Tanzania. The study, which was initiated in early 2007, will include 200 female participants.

l

Completed and presented results from

This project will generate critical data on the needs

vaginal ring study

and preferences of women and their male partners, in

Results from the second IPM dapivirine vaginal ring

preparation for the eventual introduction of and access

study were presented at the XVI International AIDS

to microbicides among user populations. Although

Conference in Toronto, Canada, in August 2006. This

vaginal rings have been used for other medical purposes

study showed that the reservoir vaginal ring was safe

in developed countries, little data exists on women’s

and well tolerated by women after seven days of use.

experiences with vaginal rings in Africa.

The study follows an earlier one conducted in 2005 with
a similarly configured vaginal ring that was also safe
and well tolerated in women after the same time of use.
Importantly, both studies demonstrated appropriate
distribution of drug in the genital tract.

10

l

Collaborated with partners to prepare for
clinical trials in africa

In 2006, IPM continued to partner with a number of scientists
and researchers based throughout Africa to develop new
research sites or improve existing ones in order to conduct
clinical studies. Moving forward, IPM will continue to

Learning what works for women
For a microbicide product to be effective, it has to
be acceptable to the women who will use it. But
what characteristics do women prefer? In 2006,
IPM teamed with three consumer market research
organisations (based in the United States, South
Africa and Kenya) to find out. The resulting Product

implement cohort and cross-sectional studies to determine

Attribute Study involved nearly 550 women

incidence rates in preparation for its first efficacy trial.

participants in Kenya, South Africa and Zambia.

These studies are being conducted in four sites near

Three different gel products were used, all

Nairobi and in Mombasa, Kenya; Nasarawa, Nigeria;

water-based placebos with no drug involved, but

Kigali, Rwanda; several locations in South Africa; and

each with a different texture and consistency, or

Moshi, Tanzania.

viscosity. Participants were asked:
l Which

For example, IPM partnered with the well-established
Kilimanjaro Christian Medical Centre in Moshi, Tanzania,

l How

gel do you prefer?

do the gels compare in terms of key

characteristics?

acceptability studies. As part of the collaboration, IPM

l

What do you like and dislike about the gels?

constructed a new clinic and supplied it with equipment

l How

do your male partners react to the gels?

necessary to carry out clinical trials. In addition to

Study participants also were asked whether

infrastructure development, IPM provided staff capacity

they would recommend the product to others,

development through Good Clinical Practices (GCP) and

and whether they had suggestions for product

colposcopy training.

improvements. The mid-range viscosity product
was generally the highest rated, receiving superior

l

Established a South African office to lead
clinical trials

IPM opened a new office near Cape Town, South Africa,
increasing internal capacity to develop and support
clinical research teams.

scores for its applicator, consistency, impact on
sexual pleasure, colour and other characteristics.
A majority of women in all three countries said
they would “definitely use” any one of the gels
– especially if it was effective against HIV.
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to conduct dapivirine gel and vaginal ring safety and

11

IPM is committed to implementing microbicide clinical
trials that meet the highest ethical and regulatory
standards, sustain broad community support and
leave participating communities better off.

Clinical Trials
TRIAL

TRIAL NAME AND LOCATION

n*

STATUS

IPM001

Dapivirine vaginal ring safety, Belgium

12

Completed, 2005

IPM003

Dapivirine gel safety, Rwanda, South Africa, Tanzania

112

Completed, 2006

IPM004

Dapivirine gel PK, South Africa

18

Completed, 2006

IPM005B

Dapivirine gel expanded safety, Belgium

36

Completed, 2006

IPM007

Seroconverter protocol, various sites

N/A

Planned, 2008

IPM008

Dapivirine vaginal ring safety, Belgium

13

Completed, 2005

IPM009

Dapivirine gel efficacy, various sites

TBD

Planned, 2008

IPM010

Dapivirine gel male tolerance, Belgium

36

Planned

IPM011

Vaginal ring acceptability, Kenya, South Africa, Tanzania

200

Ongoing

IPM012

Dapivirine gel PK, TBD

TBD

Q3, 2007

IPM013

Dapivirine vaginal ring PK, Belgium

60

Q3, 2007

IPM014

Dapivirine gel safety, South Africa, TBD

TBD

Q4, 2007

IPM015

Dapivirine vaginal ring safety, South Africa, Tanzania

200

Q3, 2007

IPM016

Small volume applicator PK, TBD

TBD

Q3, 2007

IPM017

Dapivirine vaginal ring safety, Belgium

TBD

Q3, 2007

IPM018

Vaginal ring feasibility, Belgium

24

Ongoing

* Estimated number of volunteers in study

12

Protecting participants’ rights and health
Guidelines for the Conduct of IPM Clinical Trials
The HIV/AIDS epidemic has its greatest impact in

Guidelines for the Conduct of IPM Clinical Trials

communities where access to health care is limited

specifies principles for:

and social inequity is a significant aspect of the lives

l

of women. These conditions create special challenges

trial development onward

for ensuring that the rights, autonomy and welfare of
clinical trial participants are protected. It is critical

Community engagement from the earliest stages of

l

Informed consent to ensure participants’ consent

that these challenges be openly and effectively

is freely given and based on a clear understanding

addressed. Only by testing microbicides in the

of the trial’s risks and potential benefits

countries most profoundly affected by HIV/AIDS can

l Risk

researchers measure the safety, effectiveness and

and female condoms

acceptability of these products among the women in most
urgent need of new, female-initiated HIV-prevention tools.
In 2006, IPM established guidelines for the conduct

l

Referral of individuals who test HIV-positive at screening,
prior to enrolment, to expedite comprehensive care

l

of its clinical trials, understanding that some aspects of

Screening and treatment of common, curable
sexually transmitted infections for trial participants

ethical clinical practice resist standardisation across
countries and trial sites and will need to be adapted to

reduction counselling and provision of male

l

ARV treatment and care for participants who become
infected with HIV during the trial

meet unique local circumstances.

Prophylactic care and treatment for study staff

l

Treatment and compensation for physical harm
incurred during the trial

l

Post-trial access to the product studied, when
demonstrated to be safe and effective, and licensed
for domestic use

l

Measuring potential social harms to women participating
in trials and addressing these concerns where possible

International Partnership for Microbicides l ANNUAL REPORT 2006
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Advancing women’s
			 access to future
						 microbicides

addressing regulatory
approval
Ensuring access is A
cornerstone of the
development process

Developing regulatory guidelines for a category of drugs

Even before the earliest development of a candidate

prevalent, it is particularly difficult. IPM has teamed

begins, IPM considers numerous factors to ensure that

with international organisations to help strengthen

finished products will get quickly into the hands of the

the regulatory capacity of developing countries. It also

women who need them most. How expensive will a po-

is helping to create stronger links between national

tential compound be to research and manufacture? Can

regulatory authorities worldwide for possible joint

royalty-free licences be obtained? What kinds of distri-

reviews of products as they emerge, and working with

bution channels can be put in place to cost-effectively

the United States Food and Drug Administration and

bring the product to market? IPM is active on all these

the European Medicines Evaluation Agency to facilitate

fronts in order to eliminate possible delays and road-

future approvals.

blocks in anticipation of product availability. It identifies
and prioritises drug candidates on the basis of multiple
factors, including ultimate affordability and availability
of manufacturing capacity, to help ensure that any
future products are accessible to women most at need.

14

that does not yet exist is a daunting problem for any
country. For resource-poor nations, where HIV is most

XVI International
aids conference
Presentations at the XVI International AIDS Conference

Increasing global awareness …
and local acceptance

held in Toronto, Canada, in August 2006 emphasised

Each year, microbicides gain increased prominence as

to succeed in sustaining treatment. The needs of women

a potentially powerful tool in the fight against HIV. IPM

in the face of the AIDS epidemic and the potential role of

helps keep leaders in the fight against HIV/AIDS current

microbicides to prevent HIV were highlighted throughout

with progress in microbicide development. IPM also

the conference. Bill Gates, in speaking about microbi-

supports advocacy groups and brings microbicides to

cides as being an important breakthrough, said: “No mat-

the attention of the media and the public.

ter where a woman lives, who she is, or what she does,

that prevention efforts must be scaled up if the world is

a woman should never need her partner’s permission to
save her life.”

International Partnership for Microbicides l ANNUAL REPORT 2006
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women’s access to future microbicides
Progress this year:
l

Served as Secretariat for Women’s

l

Hosted microbicide briefing in Kenya

Leadership Network for Microbicides

IPM updated approximately 50 representatives from

In 2006, one of the world’s most recognised and

donor, multilateral and international organisations on

respected women, Graça Machel, began the Women’s

microbicide development in May 2006. Speakers at the

Leadership Network for Microbicide Development.

Nairobi, Kenya, event included the Honourable Charity

Members include Melinda Gates, Hilde Johnson,

Ngilu, Kenyan Minister of Health, and Ambassador Stephen

Wangari Maathai, Gertrude Mongella, Joy Phumaphi,

Lewis, UN Special Envoy for HIV/AIDS in Africa.

Mary Robinson, Zeda Rosenberg and Mirta Roses
Periago. IPM helped arrange an initial gathering of

l

Initiated international working group of

grassroots microbicide advocates with Graça Machel

women living with HIV and microbicide

during Microbicides 2006 in Cape Town, South Africa,

researchers

to discuss how the high-level network members could

IPM facilitated a six-month series of issue-based

best generate awareness and political support for

dialogues among HIV-positive women, advocates

microbicide development.

for microbicides, microbicide scientists and product
developers. These discussions were an opportunity
to share concerns and discuss research issues of
importance to HIV-positive women.

“HIV/AIDS policies and resource
expenditure need to reflect the reality of the
pandemic’s spread and impact on women
and girls. We need increased investment to
develop effective microbicides as a crucial
part of HIV-prevention programmes.”
16

— Graça Machel

IPM identifies and prioritises drug
candidates on the basis of multiple
factors, including ultimate affordability and availability of manufacturing capacity, to help ensure that
any future products are accessible
to women most at need.

l

Increased financial support from funders

Belgium, Canada, Denmark, the European Commission,
France, Germany, Ireland, Norway, the Netherlands,
Sweden, the United States and the United Kingdom

From research to reality:
Clearing the way for product
introduction
IPM 2006 Access Forum
Past experience indicates that countries in the

ment to microbicide development and clinical trials.

developing world lack sufficient infrastructure

IPM’s other funders include the Bill & Melinda Gates

and financing to connect citizens with important

Foundation, the Rockefeller Foundation, UNFPA and

product innovations. IPM is committed to preparing

the World Bank.

markets in advance of microbicide product
availability, so women most at risk will have

l

Reviewed four countries for readiness

access to microbicides as quickly as possible.

IPM commissioned readiness studies for India, Nigeria,

Towards this end, IPM hosted a one-day forum,

Rwanda and Tanzania. These profiles surveyed each nation’s

“Understanding Microbicide Introduction in Africa

potential readiness for microbicide development and

and India” in Toronto, Canada, during the XVI

introduction in terms of its policies, health system,

International AIDS Conference. Leading experts

manufacturing, and economic and social infrastructure.

in microbicides, HIV/AIDS and reproductive health
presented their previous experience in introducing
new products in India, Nigeria, Rwanda, South
Africa, Tanzania and Zambia.

International Partnership for Microbicides l ANNUAL REPORT 2006

initiated, renewed or increased their financial commit-
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financial report
Consolidated Balance Sheet, Year Ended December 31, 2006. Amounts shown in US dollars.

Assets

Liabilities and Net Assets
$81,897,654

Cash and cash equivalents

Liabilities

Accounts receivable 		

$812,017

Accounts payable and accrued expenses

Prepaid expenses and other assets

$420,472

Deferred revenue 			

Prepaid rent and maintenance, net

$522,461

$3,559,039
$68,814,364
$72,373,403

$1,697,498

Property and equipment, net

$85,350,102

Total assets:

Net assets

Unrestricted 			
Temporarily restricted 			

$1,116,166
$11,860,533
$12,976,699

Total liabilities and net assets:

$85,350,102

Expenses by Department*
12%

5%

Funding considerations

15%

Conducting clinical trials in developing countries requires
substantial investments. Since 2002, IPM has raised a
15%

total of $217 million (funds received plus future commitments to be received), with almost $84 million of
that funding available as of December 31, 2006. IPM has
35%
18%

undertaken resource development efforts understanding
that funding commitments to complete efficacy trials
should be in hand before the trials can commence, as

Research and development

External relations

ethical review boards generally will not approve conducting

Clinical programs

Project management

a trial without sufficient funds required for completion.

Site development

General and administrative

An efficacy trial necessary to support licensure for a
single microbicide product requires enlisting thousands

* Year Ended December 31, 2006. Total expenses $25.5 million.

of women and following them for an extended period
of time so researchers can compare infection rates
among women who use a candidate microbicide with
those using a placebo. A single efficacy trial can cost
as much as $70-$120 million. Multiple efficacy trials for
microbicide products will be needed, thereby making
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IPM’s future financial need significant.
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Board of Directors
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Belgian Development Cooperation
Canadian International Development Agency
Denmark Ministry of Foreign Affairs
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Deputy Prime Minister, The Netherlands

Dr. Alex Coutinho (Vice-Chair)
Executive Director - The AIDS Support Organisation,
Uganda

Mr. Rajat Gupta
Senior Partner Worldwide - McKinsey & Company, USA

Dr. Seth Harrison
Managing General Partner - Apple Tree Partners, USA

Germany Federal Ministry for Economic
Cooperation and Development
Irish Aid, Department of Foreign Affairs
The Netherlands Ministry of Foreign Affairs
Norwegian Royal Ministry of Foreign Affairs

Dr. David Kessler
Dean - University of California, San Francisco School of
Medicine, USA

Ms. Anjali Nayyar
Vice-President of Country and Regional Programmes
International AIDS Vaccine Initiative, USA

Dr. Albert Profy

The Rockefeller Foundation

Vice-President, Preclinical Development - Indevus
Pharmaceuticals, Inc., USA

Sweden Ministry for Foreign Affairs
Sweden, the Department for Research
Cooperation

Chief Executive Officer - IPM, USA

Dr. Hélène Rossert-Blavier
Director General - AIDES, France

Ms. Anandi Yuvaraj
Program Manager for HIV and Sexual Reproductive

United Nations Population Fund
United States Agency for International
Development
The World Bank

Health - PATH, India
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United Kingdom, Department for International
Development

Dr. Zeda F. Rosenberg
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Scientific Advisory Board
Executive Committee
Dr. Robin Shattock, Chair
St. George’s, University of London, United Kingdom

Dr. Richard Bax
Bax Consulting, United Kingdom

Mr. Ben Cheng
The George Washington University, USA

Dr. Gustavo F. Doncel
CONRAD of the Eastern Virginia Medical School, USA

Dr. Sharon L. Hillier
University of Pittsburgh, USA

Dr. Ruth Merkatz
Population Council Center for Biomedical Research, USA

Dr. Thomas Moench
ReProtect, Inc., USA

Dr. Lynn Paxton
Centers for Disease Control and Prevention, USA

Dr. Gita Ramjee
Medical Research Council, South Africa

Dr. Martin Springer
Merck & Co., Inc., (Retired), USA

Dr. Jens Van Roey
Médecins Sans Frontières, Switzerland
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Ms. Karen Douville
Executive Director for Project Management

Dr. Jennifer Nadeau
Executive Director for Communications
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2006 international Partners
Advanced Biosciences Laboratory, USA

Family Health International, USA

AIDES, France

German Foundation for World Population (DSW), Germany

AIDS Fondet, Denmark

Gilead Sciences, Inc., USA

Alliance for Microbicide Development, USA

Global Campaign for Microbicides, USA

Analytical Solutions, USA

Harvard School of Public Health, USA

BePart Community Research Solutions; Drakenstein
Hospice, South Africa

Health and Development Africa, South Africa

Bristol-Myers Squibb, USA
CBR Institute for Biomedical Research, USA
Centers for Disease Control and Prevention, USA

Imquest Biosciences, USA
Innovative Biotech Ltd., Nigeria
Institute of Tropical Medicine, Belgium

Clinical Research Centres SA, South Africa

Instituto Nacional de Saude (Mozambican National
Institute of Health), Mozambique

Clinton Global Initiative, USA

Interagency Coalition on AIDS and Development, Canada

CONRAD, USA

International Antiviral Therapy Evaluation Center,

Cornell University, USA
Deseret International Foundation, Namibia
Desmond Tutu HIV Foundation, South Africa
Equilibres & Populations, France
European Microbicide Project, United Kingdom

The Netherlands

International Centre for Reproductive Health, Kenya
Johns Hopkins University, USA
J-Star Research, USA
Kenya Medical Research Institute, Kenya
Kilimanjaro Christian Medical Centre, Tanzania
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Locus Pharmaceuticals, USA

SGS Life Science Services, Belgium

London School of Hygiene and Tropical Medicine,

Society for Women and AIDS in Africa, Namibia

United Kingdom

Madibeng Centre for Research, South Africa
McGill University, Canada

Statistics Collaborative, USA
St. George’s, University of London, United Kingdom

Medical Research Council, South Africa

Tibotec Pharmaceuticals, Ltd. (a subsidiary of Johnson
& Johnson), Belgium

Medical Research Council, Uganda

UNAIDS, Global Coalition on Women and AIDS, Switzerland

Merck & Co., Inc., USA

University of Auckland, New Zealand

Microbicide Development Programme, United Kingdom

University of California, Los Angeles, USA

Mintaka Foundation, Switzerland

University of Ghent, Belgium

Mount Sinai School of Medicine, USA

University of the Free State, South Africa

National AIDS Trust, United Kingdom

University of the Witwatersrand, Reproductive Health
and HIV Research Unit, South Africa

National Institute for Research in Reproductive Health, India
National Institute of Allergy and Infectious Diseases, USA
Novovax, USA
Paragon Medsystems, USA
Particle Sciences, USA
Population Council, USA
Projet Ubuzima, Rwanda
Queen’s University Belfast, United Kingdom

University of Utah, USA
University of Zimbabwe, Zimbabwe
Urban Research and Development Centre for Africa, Kenya
Voxiva, USA
Warner Chilcott, United Kingdom
World Health Organization, Switzerland
Xigo Nanotools, USA

Regulatory Compliance Initiatives, USA

Research Triangle Institute, USA
ScinoPharm, Taiwan
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Scientific Publications and abstracts
supported by IPM in 2006

Coplan, P., I. Malonza, M. Mitchnick and Z. Rosenberg.

Johnson, S., L. Connell, R. Govender, D. Nowitz,

2006. Methods to estimate HIV-1 incidence among

V. Tallis and E. McGrory. 2006. Getting a microbicide

study populations prior to microbicide efficacy trials.

into the field in South Africa: What would it take?

Poster presentation at the Microbicides 2006

Oral presentation at the Microbicides 2006 Conference,

Conference, Cape Town, South Africa.

Cape Town, South Africa.

Douville, K., J. Romano and S. Race. 2006. Challenges

Kiser, P., C. Lee, H. Aliyar and K. Gupta. 2006. Novel

in microbicide production during the drug development

delivery systems for microbicides: Seven triggered

lifecycle. Poster presentation at the Microbicides

release and in situ gelling polymer carriers. Oral

2006 Conference, Cape Town, South Africa.

presentation at the Microbicides 2006 Conference,
Cape Town, South Africa.

Douville, K., M. Mitchnick, L. Baker and D. Studebaker.
2006. Modeling phase III microbicide clinical trial

Lee, C., H. Aliyar, K. Gupta and P. Kiser. 2006.

costs. Poster presentation at the XVI International

Triggering microbicide release with enzymes in

AIDS Conference, Toronto, Canada.

semen. Poster presentation at the Microbicides
2006 Conference, Cape Town, South Africa.

Fairhurst, D., D. Perumal, R.J. Shattock, T. Cosgrove,
E. Hasan, J-L. Brousseau, J. Romano and M. Mitchnick.

Martinez, J., P. Coplan and M.A. Wainberg. 2006. Is HIV

2006. Variability in the structure-function character-

drug resistance a limiting factor in the development of

istics of poly(styrene-sulphonate) macromolecules

anti-HIV NNRTI and NRTI-based vaginal microbicide

impinges the efficacy of in-vitro HIV-1 inhibition.

strategies? Antiviral Research 71 (Sept.): 343-350.

Poster presentation at the Microbicides 2006
Conference, Cape Town, South Africa.

Methot M., P. Harrison, L. Heise, V. Raghavendran,
Z. Rosenberg, B. Shearer and J. Baum. 2006. An intense

Fairhurst, D., R. Rowell, S. Key, I. Monahan, D. Stieh,

global advocacy campaign to seek endorsement from

F. McNeil-Watson, A. Morfesis, M. Mitchnick and

G8 countries. Oral presentation at the Microbicides

R.J. Shattock. 2006. Electrophoretic fingerprinting

2006 Conference, Cape Town, South Africa.

of HIV-1 cell interaction: A novel tool for development
of charge-based strategies. Poster presentation

Nuttall, J., D. Thake, M. Lewis, J. Ferkany, J. Romano

at the Microbicides 2006 Conference, Cape Town,

and M. Mitchnick. 2006. Concentrations of dapivirine

South Africa.

in the rhesus macaque and rabbit following once-daily
intravaginal administration of a gel formulation of [14c]
dapivirine for seven days. Poster presentation at the
Microbicides 2006 Conference, Cape Town, South Africa.
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Orner, P., J. Harries, D. Cooper, J. Moodley, M. Hoffman,

Rosenberg, Z. 2006. Status of microbicide product

J. Becker, E. McGrory, R. Dabash and H. Bracken. 2006.

development to prevent HIV transmission. Panel

Challenges to microbicide introduction in South

presentation at the HIV DART 2006 Conference,

Africa. Social Science & Medicine 63 (Aug.): 968-978.

Cancun, Mexico.

Perumal, D., R.J. Shattock, G. Gwozdz, L. Goldman,

Van de Wijgert, J., J. Vyankandondera, P. Coplan,

P. Mesquita, G. Wallace, J. Romano, D. Fairhurst and

N. Veldhuijzen, M-M. Umulisa, E. Geubbels, C. Tuijn,

M. Mitchnick. 2006. Novel TMC120 gel formulation

K. Ford, J. Ntirushwa and E. Kayirangwa. 2006.

demonstrates potent anti-HIV-1 activity in cellular

Establishing a new microbicide trial site in Rwanda.

and human cervical tissue models. Oral presentation

Poster presentation at the Microbicides 2006

at the Microbicides 2006 Conference, Cape Town,

Conference, Cape Town, South Africa.

South Africa.
Veldhuijzen, N., J. Nyinawabega, M. Umulisa,
Race, S., K. Barnhart, D. Fairhurst, K. Chubb,

B. Kankindi, E. Geubbels, P. Basinga, J. Vyankandondera

J. Romano and D. Katz. 2006. The rheological

and J. van de Wijgert. 2006. Preparing for microbicide

properties of vaginal gels critically affect spreading

trials in Rwanda: Focus group discussions with

characteristics within the vagina. Poster presentation

Rwandan women and men. Culture, Health &

at the Microbicides 2006 Conference, Cape Town,

Sexuality 8 (Sept.): 395-406.

South Africa.
Walker, S., T. Mattholie, S. West and V. Raghavendran.
2006. A framework for future microbicide access in

and in vivo delivery of TMC120 with an intravaginal

developing countries. Poster presentation at the XVI

ring: Implications for microbicide delivery. Oral pre-

International AIDS Conference, Toronto, Canada.

sentation at the XVI International AIDS Conference,
Toronto, Canada.

Woolfson, A.D., R.K. Malcolm, R.J. Morrow, C.F. Toner
and S.D. McCullagh. 2006. Intravaginal ring delivery

Romano, J. 2006. Multiple dosage forms of the

of the reverse transcriptase inhibitor TMC120 as an

NNRTI microbicide dapivirine: Product development

HIV microbicide. International Journal of Pharma-

and evaluation. Oral presentation at the Institute of

ceutics 325 (15 Nov.): 82-89.

Human Virology 2006 International Meeting,
Baltimore, USA.

International Partnership for Microbicides l ANNUAL REPORT 2006

Romano, J. 2006. Characterization of in vitro release
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